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eeling-Off Labels
ounting Evidence for
enefit of Drug-Eluting
tents With Off-Label Use*
einz Joachim Büttner, MD,
ranz-Josef Neumann, MD
ad Krozingen, Germany
n the basis of the results of the pivotal randomized trials
n sirolimus- (SES) or paclitaxel-eluting stents, the Food
nd Drug Administration (FDA) approved the use of
rug-eluting stents (DES) for previously untreated coronary
esions of30 mm in length and a reference vessel diameter
f 2.50 to 3.75 mm (1). The risk of target vessel revascu-
arization (TVR) in these relatively simple lesions, however,
s fairly low, thus limiting the potential benefit from DES.
t is intuitive that the absolute reduction in TVR by DES as
ompared with bare-metal stents (BMS) might be substan-
ially larger in the more complex lesions outside the labeling
or DES, which carry a high risk of restenosis. Hence, it is
ot surprising that an estimated 60% of the use of DES is
ff label (1). Nevertheless, the safety of this practice is still
matter of debate.
See page 2029
Meta-analyses of pivotal trials on DES, reported at the
uropean Society of Cardiology meeting in Barcelona in
006, suggested an excessive long-term risk of death and
yocardial infarction (MI) with DES as compared with
MS (2). These analyses, however, were flawed by the use
f study-level data. Reanalysis of the same data sets with
atient-level data did not confirm the earlier reports (3): for
he pivotal trials of both SES and paclitaxel-eluting stents,
he incidence of death and MI during 4-year follow-up after
lacement of DES was not significantly different from that
fter BMS (3). These reassuring results were challenged by
larming observations during 3-year follow-up of the Swedish
oronary Angiography and Angioplasty Registry (SCAAR)
4). This registry comprised 19,771 consecutive patients un-
ergoing percutaneous coronary intervention, 6,033 thereof
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
ollege of Cardiology.o
From the Herz-Zentrum, Bad Krozingen, Germany. Dr. Büttner has received
ecture honoraria from Cordis and Boston Scientific.reated with DES, and 13,738 treated with BMS (4). After
he initial 6 months, when clopidogrel was usually discon-
inued, SCAAR found an absolute increase of 0.5% in the
isk of deaths per year associated with DES and an absolute
ncrease in the composite of death and MI of 0.5% to
.0%/year (4). The discrepancy in the results of the pivotal
rials was attributed to differences in patient selection. The
ivotal trials included patients on the basis of selection
riteria that subsequently constituted the FDA-approved
n-label use of DES. In SCAAR, however, most of the use
f DES was off-label. Hence, it was speculated that off-label
se of DES was associated with an excessive late risk of
eath and MI. The FDA thus cautioned against the
ff-label use of DES (1).
As an alternative explanation, the discrepancy between
CAAR and the pivotal trials might be attributed to the
onrandomized nature of SCAAR. In SCAAR, the sicker
atients with a poorer prognosis might have been assigned
redominantly to DES. Although propensity-score meth-
ds were used to compensate for this, differences in baseline
haracteristics or selection criteria that might not have been
ecorded could remain (4). Indeed, some important variables,
uch as lesion length, reference vessel diameter and left ven-
ricular ejection fraction, could not be included in the analysis.
s the authors of SCAAR state in their manuscript, “random-
zed studies with an adequate number of patients and long-
erm follow-up” are needed to clarify the long-term safety and
fficacy of the off-label use of DES (4).
Up to now, no single study fulfills these requirements.
owever, Kastrati et al. (5,6) performed a meta-analysis of
7 randomized trials with SES, among them 13 trials
omprising 3,467 patients addressing off-label indications.
n this analysis, off-label use of SES as compared with BMS
as associated with a relative risk of 0.97 (95% confidence
nterval [CI] 0.70 to 1.33) for death and 0.88 (95% CI 0.51
o 1.52) for stent thrombosis (5,6). For on-label indications,
owever, SES were associated with a relative risk of 1.04
95% CI 0.75 to 1.46) for death and 1.60 (95% CI 0.53 to
.82) for stent thrombosis (5,6). The odds ratios comparing
ES with BMS for major adverse cardiac events, largely
riven by TVR, were similar, irrespective of on-label or
ff-label use, and highly favored the use of SES (5). Currently
vailable data from randomized studies on off-label indications,
ence, strongly suggest the use of SES in this setting.
It is the role of large registries to verify whether the
esults of randomized studies are applicable to daily practice.
n this respect, the findings from the National Heart, Lung,
nd Blood Institute’s Dynamic Registry reported in this
ssue of the Journal represent an important milestone (7).
his registry comprises the full spectrum of patients treated
ith DES in North America; 1,460 patients who received at
east one DES in 2004 were compared with 1,763 patients
nrolled in the recruitment period immediately preceding
he approval of DES (2001 to 2002) who received at least
ne BMS (7). During 1-year follow-up, the cumulative
i
w
t
r
(
T
r
c
o
t
p
t
i
s
e
e
f
o
o
i
3
i
d
o
l
d
s
t
h
A
c
t
p
m
m
i
t
s
fi
r
e
t
l
d
D
W
(
f
a
3
A
s
l
a
e
c
r
r
c
s
(
r
s
r
c
r
u
s
p
p
R
H
G
R
1
1
1
1
2038 Büttner and Neumann JACC Vol. 50, No. 21, 2007
Editorial Comment November 20, 2007:2037–8ncidence of death and MI was 7.6% with DES and 8.7%
ith BMS (adjusted hazard ratio [HR] 0.88, 95% CI 0.68
o 1.15, p  0.34), and the incidence of any repeat
evascularization was 8.3% after DES and 14.9% after BMS
adjusted HR 0.38, 95% CI 0.25 to 0.60, p  0.001) (7).
he authors thoroughly investigated their cohort with
espect to lesion characteristics that indicate complexity and
onstitute off-label use. Consistent with the meta-analysis
f the randomized trials on off-label indications for DES,
he HRs for the 1-year rate of death and MI, adjusted for
ertinent covariables, favored DES over BMS by trend in
he presence of any criterion for lesion complexity, whereas
n absence of any criterion for lesion complexity, the 1-year
afety of DES and BMS was almost identical (7). Consid-
ring the 1-year incidence of TVR, DES were similarly
fficacious irrespective of the presence or absence of criteria
or lesion complexity (7).
Two recent registries indicated that the safety and efficacy
f DES is reduced in off-label use as compared with
n-label use. Both the EVENT (Evaluation of Drug Elut-
ng Stents and Ischemic Events) (8) registry, comprising
,323 patients, and the D.E.S.cover Registry (9), compris-
ng 5,541 patients, reported a significantly increased risk of
eath and MI early (30 days) after placement of DES for
ff-label indications as compared with placement for on-
abel indications but no significant further increase in the
ifference between on-label and off-label use during the
ubsequent months up to 1 year. In addition, in both studies
he need for TVR during 1-year follow-up was significantly
igher after off-label use than after on-label use (8,9).
lthough neither EVENT nor D.E.S.cover had a BMS
omparator, the authors of EVENT cautioned about ex-
rapolating the benefits of DES over BMS observed in the
ivotal trials to higher-risk clinical settings (8). It is the
erit of the Dynamic Registry (7) to shed more light on this
atter. Although the efficacy and safety of DES might be
nferior in off-label use compared with that in on-label use,
he Dynamic Registry clearly demonstrates that DES are
till superior to BMS used in the same setting (7). These
ndings concur with currently available evidence from
andomized studies (5,6).
The termination of follow-up at 1-year has to be consid-
red as an important limitation of the Dynamic Registry. In
his respect, we are lucky to have other large registries with
onger follow-ups: REAL (REgistro AngiopLastiche
ell’Emilia Romagna) with 10,629 patients (n 3,064 with
ES, n  7,565 with BMS) and 2-year follow-up (10); the
estern Denmark Heart Registry (11) with 12,395 patients
n  3,548 with DES, n  8,247 with BMS) and 15-month
ollow-up; as well as ARTS (Arterial Revascularization Ther-
pies Study) II comprising 607 patients with SES followed for
-years and a historic control of 600 patients with BMS from
RTS I (12,13). In each of these registries, the majority of
tents were implanted for indications not covered by current
abeling. No significant difference in the composite of death
nd MI between DES and BMS was found during thentire follow-up in any of the 3 registries (10–13). In
ontrast, the need for repeat interventions was significantly
educed in each of the 3 registries with adjusted HRs in the
ange of 0.5 to 0.7 (10–13).
We believe that the Dynamic Registry makes an important
ontribution to the discussion of the use of DES in lesion
ubsets that are not yet covered by the FDA-approved labeling
7). Many of these lesion subsets carry a very high risk for
estenosis. The mounting evidence on this matter confirms the
uperior efficacy of DES with respect to the prevention of
epeat revascularization and does not suggest inferior safety
ompared with BMS. Nevertheless, the acute and long-term
isk in off-label indications will be higher than with on-label
se. Thus, alternative treatment strategies, specifically bypass
urgery, deserve serious consideration. Once the decision for
ercutaneous coronary intervention has been made, DES
robably will be the best choice in most instances.
eprint requests and correspondence: Dr. Franz-Josef Neumann,
erz-Zentrum Bad Krozingen, Südring 15, 79189 Bad Krozingen,
ermany. E-mail: franz-josef.neumann@herzzentrum.de.
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